Indications
Ledaga is indicated for the topical treatment of mycosis fungoides-type cutaneous T-cell lymphoma (MF-type CTCL) in adult patients.
Composition
- Active substance
- chlormethine
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Ledaga
- Active substance
- chlormethine
- ATC code
- L01AA05
- Therapeutic area
- Mycosis Fungoides
- Marketing authorisation holder
- Helsinn Birex Pharmaceuticals Ltd.
- Status
- Authorised
- EU authorisation
- 3 Mar 2017